Balancing safety and efficacy: Focus on endometrial protection

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 45, Issue 3 SUPPL., 2000, Pages 273-284

  Boroditsky, Richard S ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Endometrial cancer; Endometrial hyperplasia; Estrogen replacement therapy; Hormone replacement therapy, postmenopausal; Progestogens

Indexed keywords

CONJUGATED ESTROGEN; DYDROGESTERONE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL; NORETHISTERONE; NORGESTREL; PIPERAZINE ESTRONE SULFATE; PROGESTERONE; PROGESTERONE RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BREAKTHROUGH BLEEDING; CANCER RISK; CONFERENCE PAPER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HORMONE STRUCTURE; HUMAN; MENSTRUAL CYCLE; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERPLASIA; MIDDLE AGED; PATIENT COMPLIANCE; POSTMENOPAUSE; PROGESTINS;

EID: 0034110067     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. American Cancer Society: Cancer Facts & Figures - 1997. Atlanta, ACS, 1997
2. de Lignieres B, Moyer DL: Influence of sex hormones on hyperplasia/carcinoma risks. In Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Edited by RA Lobo. New York, Raven Press, 1994, pp 373-383
3. Paterson MEL, Wade-Evans T, Sturdee DW, et al: Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980;280:822-825
4. Shapiro JA, Weiss NS, Beresford SAA, et al: Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 1998;9:99-101
5. Notelovitz M, Varner RE, Rebar RW, et al: Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menopause 1997;4:80-88
6. Sturdee DW: Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Int J Fertil 1996;41:22-28
7. The Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1996;275: 370-375
8. Pike MC, Peters RK, Cozen W, et al: Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116
9. Beresford SAA, Weiss NS, Voigt LF, et al: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-461
10. Casper RF: Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil 1996;41:16-21
11. Greb RR, Heikinheimo O, Williams RF, et al: Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum Reprod 1997;12:1280-1292
12. Li X-F, Ahmed A: Dual role of angiotensin II in the human endometrium (abstr). Hum Reprod (suppl 2) 1996;11:95-108
13. Faulkner DL, Young C, Hutchins D, et al: Patient noncompliance with hormone replacement therapy: A nationwide estimate using a large prescription claims database. Menopause 1998;5:226-229
14. Björn I, Bäckström T: Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86
15. Ryan PJ, Harrison R, Blake GM, et al: Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992;99: 325-328
16. Dören M, Schneider HPG: Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Maturitas 1996;25:99-105
17. Moyer DL, de Lignieres B, Driguez P, et al: Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992-997
18. Kim S, Korhonen M, Wilborn W, et al: Antiproliferative effects of low-dose micronized progesterone. Fertil Steril 1996;65:323-331
19. Panay N, Studd J: Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159-171
20. de Lignieres B: Oral micronized progesterone. Clin Ther 1999;21:41-60
21. Kimzey LM, Gumowski J, Merriam GR, et al: Absorption of micronized progesterone from a nonliquefying vaginal cream. Fertil Steril 1991;56:995-996
22. Gambrell RD Jr: Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 1997;177:1196-1207
23. Luciano AA, De Souza MJ, Roy MP, et al: Evaluation of low-dose estrogen and progestin therapy in postmenopausal women: A double-blind, prospective study of sequential versus continuous therapy. J Reprod Med 1993;38:207-214
24. Gelfand MM, Ferenczy A: A prospective 1-year study of estrogen and progestin in postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989;74:398-402
25. Leather AT, Savvas M, Studd JWW: Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991;78:1008-1010
26. De Leo V, la Marca A, Morgante G, et al: Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas 1999;31:171-177
27. Ettinger B, Selby J, Citron JT, et al: Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700
28. Bjarnason K, Cerin A, Lindgren R, et al: The Scandinavian Long Cycle Study Group: Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 1999;32:161-170
29. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1995;273: 199-208
30. The Writing Group for the PEPI Trial: Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;276:1389-1396
31. Espeland MA, Marcovina SM, Miller V, et al: For the PEPI investigators: Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998;97:979-986
32. DuPont A, Dupont P, Cusan L, et al: Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991;13:297-311
33. Gillet JY, Andre G, Faguer B, et al: Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose: A multicenter study. Maturitas 1994;19: 103-115
34. Lorrain J, Lalumière G, Caron P: The effects of oral micronized progesterone on bleeding patterns, endometrial histology and bone density in postmenopausal women on hormone replacement therapy. Int J Gynecol Obstet 1994; 46(suppl 1):77
35. Davies GC, Huster WJ, Shen W, et al: Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999;6:188-195
36. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647
37. Karakoc B, Erenus M: Compliance considerations with hormone replacement therapy. Menopause 1998;5:102-106
38. McKinney KA, Thompson W: A practical guide to prescribing hormone replacement therapy. Drugs 1998;56:49-57
39. Rozenberg S, Vandromme J, Kroll M, et al: Managing the climacteric. Int J Fertil 1999;44:12-18